New tool predicts risk of drug turning toxic in the body
Source: Stephen C Dickson / Wikimedia Commons
Researchers at Cardiff University have developed a quantitative risk assessment tool to predict the likelihood of a drug either turning into a toxic version of itself, or losing efficacy, once it has entered the body.
The predictive tool, which was developed in collaboration with Liverpool John Moores University and AstraZeneca, enables the user to trawl through large databases of pharmaceutical drugs and assess the likelihood of a drug undergoing a process called ‘racemisation’, whereby the drug flips into a mirror image of itself and consequently becomes either inert, or harmful. This is thought to be the result of interaction between the drug and aqueous conditions in the body.
Racemisation, described by the researchers as a “cruel blind spot”, can result in wasted material and human resources, as well as potential harm to the user. It is hoped this new tool will lead to a significant reduction in the financial risk associated with drug development and increase the efficacy and safety of new drugs.
Drug compounds often exist in either a right- or left-handed form, each with an identical chemical composition but a structure that is a mirror image of each other and therefore non-superposable. These different forms of the same drug are known as enantiomers, meaning ‘opposite’, and often only one of the enantiomers is responsible for the desired effect while the other might be inactive or result in an adverse effect.
A famous example of this is thalidomide, first marketed in 1957, which was withdrawn from the market when it was found to cause birth defects. One enantiomer of the drug caused a sedative effect, as wanted, while the other led to birth defects.
“Following the thalidomide disaster, researchers worldwide have focussed on making compounds enantioselectively — that is containing just one enantiomer,” explained Niek Buurma, lead author of the study and a lecturer in physical organic chemistry at Cardiff University.
“However, while compounds are routinely tested to ensure they are inherently stable under physiological conditions, not much thought has been given to how to prevent configurational instability at the design stage, using suitable predictive models.”
Buurma said that he believed that the risk assessment would make it possible to manufacture safer medication by helping the pharmaceutical industry to quickly spot medication that will fail during development and focus their efforts on compounds that are more likely to work.
Citation: The Salvadore DOI: 10.1211/PJ.2018.20204203
Recommended from Pharmaceutical Press
Prescribing Medicines for Children is designed to improve understanding on all aspects of paediatric prescribing, from the development of suitable drugs through to their practical administration.£60.00
Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.£38.00
FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.£25.00
Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.£43.00
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£38.00